Pharming reports positive Phase II data
- Phase II trial of leniolisib showed 26.4% mean spleen volume reduction
- Lymph node size reduced by 33.7% in index lesions
- Pulmonary function improved with 8.0% increase in DLCO
PHAR
Pharming Group N.V. SEC filings
Every EDGAR filing for Pharming Group N.V. (PHAR), newest first, with AI summaries and stories.
- Ticker
- PHAR
- CIK
- 1828316
- Latest filing
- 5d
Filings
6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 20-F/APharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 20-FPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE 6-KPharming Group N.V.PHARLIVE